Test for First-Episode Psychosis (FEP) prognosis

Desarrollado por: Instituto de Investigación Sanitaria Hospital Clinic de Barcelona - IDIBAPS


Unmet need

Currently, only 25% of patients treated with antipsychotic drugs show a complete response to treatment. The scientific and medical community is highlighting the need of finding biomarkers liable to predict, at early stages of the disease, the response to treatment.

There are not biomarkers for the diagnosis and/or prognosis of FEP currently applied in clinical routine.

Technology description

Our technology aims to provide an accurate tool to determine the best pharmaceutical treatment for each FEP patient. It is based in the determination of the expression of some receptors in peripheral blood samples.

The advantages of this new test are:

 Non invasive, standardized technique

 Predicts the response to FEP treatment

 Useful as companion diagnostic

Estado de protección

Intellectual Property

A Spanish priority patent application was filed in June 2015 at the Spanish Patent Office (P201530918). An international PCT application has been filed on June 2016.

The Centro de Investigación Biomédica en Red (CIBER) is leading the intellectual property and commercialization of this project.

Cooperación que se desea

Commercial Opportunity

CIBER is seeking an industrial partner for licensing out and to further develop this technology.

FCRB works in partnership with Hospital Clinic, an academic hospital within the most productive scientific and medical communities in Spain.

Datos de Contacto

93 227 9165/ ktt@idibaps.org

Tecnología sanitaria:
Biotecnología y Diagnóstico Molecular (proteómica, genómica, etc...)